Jyong Biotech Ltd. Ordinary Shares (MENS)
Stock · NASDAQ · Health Care
$1.85as of 10/16/2026
Price chart
Active signals
MENS Signal Track Record
How signals performed across all stocks →What MENS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 3 | -5.1% | 33% | September 21, 2026 |
| Bollinger Band Breakout | 3 | -19.8% | 0% | August 27, 2026 |
| Any 20-session window (baseline) | -3.6% | 39% |
Computed by MarketWall from daily closing prices since April 2, 2026. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MENS
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bl…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 27
- Website
- jyongbio.com/
Fundamentals
- 1-day range
- $1.95$2.07
- Market cap
- $153.58M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-0.08
- Dividend yield
- —
- Beta
- 1.34
- Avg. volume
- 44.2K
Jyong Biotech Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- MENSJyong Biotech Ltd. Ordinary Shares$1.84▼ 7.07%Market cap $153.58MP/E —$1.43$63
- AARDAardvark Therapeutics Inc. Common Stock$3.78▼ 2.07%Market cap $159.75MP/E —$3.35$16.6
- MISTMilestone Pharmaceuticals Inc. Common Shares$0.707▼ 11.07%Market cap $146.91MP/E —$0.7075$3.06
- ADCTADC Therapeutics SA Common Shares$1.4▼ 6.04%Market cap $143.73MP/E —$0.7796$4.98
- CNTNCanton Strategic Holdings Inc. Common Stock$1.7▼ 9.36%Market cap $143.45MP/E —$1.75$6.89
- NKTXNkarta Inc. Common Stock$1.8▼ 6.74%Market cap $163.84MP/E —$1.7$3.72
- NGENNervGen Pharma Corp. Common stock$1.59▼ 1.85%Market cap $141.37MP/E —$3.2$8.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MENS Jyong Biotech Ltd. Ordinary Shares | $153.58M | — | $1.84 | ▼ 7.07% | $1.43$63 |
| AARD Aardvark Therapeutics Inc. Common Stock | $159.75M | — | $3.78 | ▼ 2.07% | $3.35$16.6 |
| MIST Milestone Pharmaceuticals Inc. Common Shares | $146.91M | — | $0.707 | ▼ 11.07% | $0.7075$3.06 |
| ADCT ADC Therapeutics SA Common Shares | $143.73M | — | $1.4 | ▼ 6.04% | $0.7796$4.98 |
| CNTN Canton Strategic Holdings Inc. Common Stock | $143.45M | — | $1.7 | ▼ 9.36% | $1.75$6.89 |
| NKTX Nkarta Inc. Common Stock | $163.84M | — | $1.8 | ▼ 6.74% | $1.7$3.72 |
| NGEN NervGen Pharma Corp. Common stock | $141.37M | — | $1.59 | ▼ 1.85% | $3.2$8.49 |
P/E shows — for peers not currently carrying a live signal of their own.
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Jyong Biotech (MENS) Announces Texas Facility for Drug Candidates
Jyong Biotech disclosed plans to build a manufacturing facility in Texas and to create a U.S. operations center. The new site is meant to support the potential commercialization of its drug candidates. This adds a tangible step toward expanding the company's production and market capabilities.
Jyong Biotech (MENS) Announces Texas Facility for Drug Candidates. Jyong Biotech disclosed plans to build a manufacturing facility in Texas and to create a U.S. operations center. The new site is meant to support the potential commercialization of its drug candidates. This adds a tangible step toward expanding the company's production and market capabilities.